Core Insights - US core inflation unexpectedly eased to a four-year low, raising questions among economists about the reliability of the data due to a prior government shutdown [8][14] - ByteDance has signed an agreement to establish a joint venture in the US with majority ownership by American investors [8][14] Market Performance - The A-share market opened lower but closed higher, with the Shanghai Composite Index up 0.16% at 3876.37 points, while the Shenzhen Component fell 1.29% and the ChiNext Index dropped 2.17% [1] - The Hong Kong market also saw fluctuations, with the Hang Seng Index closing up 0.12% at 25498.13 points, while the Hang Seng Tech Index fell 0.73% [1][5] Economic Indicators - The US core Consumer Price Index (CPI) rose by 2.6% year-on-year in November, while the overall CPI increased by 2.7% [14] - The report indicated that core CPI only increased by 0.2% over the last two months, with declines in hotel, leisure, and clothing prices limiting the overall increase [14] Corporate Developments - TikTok announced the establishment of a joint venture with US investors, which will operate independently and manage US data protection and algorithm security [8][14] - China has reportedly ordered 7 million tons of US soybeans, achieving over half of the procurement target set during the Trump administration [8][14]

Group 1 - Two studies published in Nature confirm the efficacy and safety of a new diabetes drug, Masitide, developed by China's Innovent Biologics and Eli Lilly, showing superior blood sugar control and weight loss compared to placebo and Dulaglutide [1] - The studies involved Phase III clinical trials with Chinese type 2 diabetes patients, demonstrating improvements in cardiovascular, liver, and kidney-related indicators [1] - Masitide is a dual receptor agonist for glucagon-like peptide-1 and glucagon, providing high-quality evidence for overweight, obese, and diabetic patients, highlighting China's research capabilities in this field [1] Group 2 - U.S. stock indices rose collectively, with the Dow Jones up 65.88 points (0.14%), S&P 500 up 53.33 points (0.79%), and Nasdaq up 313.04 points (1.38%), driven by gains in large tech stocks [2] - Notable stock performances included Tesla rising over 3%, and Micron Technology increasing over 10% [2] - Chinese concept stocks also saw gains, with Zhihu up over 3% and XPeng Motors up over 2% [2] Group 3 - The State Council of China issued an opinion to combat illegal tobacco activities, focusing on countering counterfeit and smuggled tobacco products, and enhancing law enforcement collaboration with other countries [3] - The opinion aims to purify the tobacco market environment and protect national interests and consumer rights [3] Group 4 - BHP CEO Mike Henry emphasized the critical role of copper in the economy and its demand surge, predicting a bull market for copper due to supply constraints [4] - The annual market size for copper is estimated between $300 billion and $400 billion, with a projected 70% increase in demand by 2050, while new mining discoveries are becoming rarer and more challenging to develop [4] Group 5 - Meituan released and open-sourced a state-of-the-art virtual human video generation model, LongCat-Video-Avatar, which supports multiple tasks and has undergone significant upgrades in realism and stability [5] Group 6 - Zhihui Mining's shares rose 126.16% in dark trading, with a planned global offering of 122 million H-shares at HKD 4.51 each, focusing on zinc, lead, and copper mining in Tibet [6] Group 7 - Evergrande Auto announced a change in the registered shareholder of its subsidiary to Guangzhou Juliyi, with stock trading suspended pending further notice [7] Group 8 - Wasion Holdings' subsidiary won a contract worth over RMB 80 million for a project with CPFL, a leading power company in Brazil, and expects significant growth in AI data center revenues [8] - The company anticipates a doubling of AI data center revenue from RMB 1 billion in 2025 to RMB 2 billion in 2026, with new orders expected to grow significantly [8] Group 9 - Citigroup raised its profit forecasts for Wasion Holdings by 1% to 5% for 2025-2027, increasing the target price from HKD 15.5 to HKD 21, maintaining a "buy" rating [9]

Core Insights - UnitedHealth Group and Eli Lilly are two leading healthcare companies, with UnitedHealth providing insurance and care services, while Eli Lilly is a major pharmaceutical player valued at $1 trillion [1] UnitedHealth Group - UnitedHealth Group has experienced a significant decline of nearly 35% since January 2025, primarily due to the removal of its insurance CEO and subsequent investigations into fraud and misconduct related to billing practices [2][4] - The company is facing unexpectedly high costs in its Medicare programs, which have negatively impacted earnings this year [4] - Management is responding by raising premiums and potentially withdrawing from certain markets, anticipating a loss of up to 1 million members from its Medicare Advantage plans, but expects these changes to enhance profitability in the long run [5] Eli Lilly - Eli Lilly's stock has surged nearly 35% in 2025, driven by its strong position in the growing market for anti-obesity drugs, with sales projected to increase from $15 billion last year to $150 billion over the next decade [2][6] - The company has achieved impressive revenue growth, reporting a 54% year-over-year increase in the third quarter [7] - Eli Lilly's pipeline includes promising anti-obesity drugs currently in phase 3 clinical trials, which could contribute to substantial growth over the next five to ten years [7]

丨2025年12月19日星期五丨 NO.1 礼来：向FDA提交新型口服减肥药orforglipron的上市申请 12月18日，礼来公司宣布，已向美国食品药品监督管理局（FDA）提交了新型口服减肥药orforglipron的 上市申请。礼来表示，从诺和诺德旗下Wegovy（司美格鲁肽）转用orforglipron的参与者，在转换后平 均维持了此前减重成果的绝大部分，仅平均反弹0.9公斤。 点评：减肥药赛道竞争趋向白热化，口服减肥药orforglipron的上市申请如能获批，将有望凭借积极的临 床数据以及口服制剂的给药优势改变目前的市场格局。 NO.2 复星医药：控股子公司与Clavis Bio达成合作，可获得至多3.63亿美元付款 12月18日，复星医药公告称，公司控股子公司复星医药产业与合作方Clavis Bio签订《合作及选择权协 议》，共同选定靶点并推进临床前开发。Clavis Bio就该等合作项目享有除中国内地、香港、澳门外的 全球范围内开发、生产及商业化独家许可的选择权。 12月18日，百济神州发布公告称，经公司董事会审议通过，同意聘任公司全球研发负责人汪来博士担任 公司总裁，全球研发负责人。聘任生效 ...

Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Long Term US Stocks to Buy Now. Eli Lilly (LLY) Gains Support From Daiwa and Goldman Sachs in Back-to-Back Calls On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 price target on the stock. That move followed a similar call from Goldman Sachs earlier. On December 15, Goldman raised its price target on Eli Lilly to $1,145 from $951 and kept a Buy rating. Momentum aro ...

Drug Efficacy and Maintenance - Lily's obesity pill shows potential as a maintenance treatment for weight loss, allowing patients to maintain weight loss without weekly injections [1] - Patients in the BGOI group regained approximately 2 pounds (约 0.9 千克) of their weight after one year [2] - Patients in the Zeppbound group regained approximately 11 pounds (约 5 千克) of their weight after one year [2] - The pill helps patients maintain the majority of weight initially lost through injections [1] Market Implications - The pill could play a significant role in the weight loss drug market as a maintenance treatment, potentially increasing drug uptake after approval [2] Pricing and Availability - The exact pricing for Novaortis or Eli Lilly's pills is currently unknown, as it is typically announced post-approval [3] - Initial doses for the pills may be priced at $150 per month for cash payments through the Trump RX direct-to-consumer website, launching in January 2026 [3] - The pricing for higher doses of the pills remains undisclosed [4]

Back to market on close. I'm Marley Caden here in Chicago alongside Sam Vodis at the New York Stock Exchange. Some final thoughts on today's session.Of course, we got the CPI report. The consumer price index rose 2.7% in November. According to the delayed data that we got from the BLS this morning that was less than the 3.1% expected, reigniting some hopes that the Fed may be able to ease more than expected.Core CPI was also cooler than anticipated, increasing 2.6% over 12 months. It was expected to have ri ...

Let's get more now on the story. Pharma and biotech reporter Anukica Kim Constantino. Anukica, what's the story here.Is this pill going to be ready soon. >> Right. So, thanks for having me on today.So, basically the news today is that Lily has trial data showing that its obesity pill could be an effective maintenance treatment for people that want to preserve their weight loss but don't want to keep taking weekly injections like Wgoian Zepbound. So in this trial, they basically followed people that initiall ...

Let's get more now on the story. Pharma and biotech reporter Anukica Kim Constantino. Anukica, what's the story here.Is this pill going to be ready soon. >> Right. So, thanks for having me on today.So, basically the news today is that Lily has trial data showing that its obesity pill could be an effective maintenance treatment for people that want to preserve their weight loss but don't want to keep taking weekly injections like Wgoian Zepbound. So in this trial, they basically followed people that initiall ...

Key Points Invest in stocks with good fundamentals, solid growth prospects, and steady dividends. These blue chip stocks have strong businesses that generate consistently strong results. With exposure to healthcare and oil and gas, they can also help diversify your portfolio. 10 stocks we like better than AbbVie › Is the S&P 500 due for a crash next year? That's a big question on the minds of many investors these days. Concerns about bubbles in tech and overall high valuations for the stock mark ...